Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.7%

16 terminated/withdrawn out of 342 trials

Success Rate

87.3%

+0.8% vs industry average

Late-Stage Pipeline

4%

12 trials in Phase 3/4

Results Transparency

17%

19 of 110 completed trials have results

Key Signals

61 recruiting19 with results12 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2
73(41.5%)
N/A
55(31.3%)
Phase 1
36(20.5%)
Phase 3
11(6.3%)
Phase 4
1(0.6%)
176Total
Phase 2(73)
N/A(55)
Phase 1(36)
Phase 3(11)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (342)

Showing 20 of 342 trials
NCT05384002Completed

An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum

Role: collaborator

NCT03144466Phase 1Terminated

A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer

Role: lead

NCT03644303Not ApplicableCompleted

Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

Role: lead

NCT04295577Completed

Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

Role: lead

NCT02437227Phase 1Completed

Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833

Role: lead

NCT02998567Phase 1Active Not Recruiting

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

Role: lead

NCT02587455Phase 1Completed

Pembrolizumab and Palliative Radiotherapy in Lung

Role: lead

NCT02562625Phase 2Terminated

Trial of Pembrolizumab and Radiotherapy in Melanoma

Role: lead

NCT04071704Completed

Assessing Health-related Quality of Life in Sarcoma Patients

Role: collaborator

NCT06681064Recruiting

Breast Cancer Evolution During Neoadjuvant Systemic Therapy

Role: lead

NCT07264088Not Yet Recruiting

Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer

Role: collaborator

NCT07002320Phase 1Recruiting

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Role: collaborator

NCT04920708Phase 2Active Not Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Role: lead

NCT07529418Not Yet Recruiting

The BALANCE Study: BlAck and Mixed Men's Lived Experience With Prostate cANCEr-Diversity in Prostate Cancer PROMS Study

Role: collaborator

NCT02819752Phase 1Terminated

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

Role: lead

NCT07503717Not ApplicableRecruiting

SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance

Role: collaborator

NCT06638541Not ApplicableRecruiting

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions

Role: lead

NCT07340632Not ApplicableNot Yet Recruiting

B4P Trial - BLOOM43 for Preconditioning

Role: collaborator

NCT07084571Recruiting

Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution

Role: lead

NCT07372885Phase 1Not Yet Recruiting

GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia

Role: collaborator